[ Long-term evaluation of the effect of a chemotherapy protocol using vincristine, adriamycin, procarbazine and prednisone (VAPP) on advanced Hodgkin's disease].
A chemotherapeutic combination associating vincristine, adriamycin, procarbazine and prednisone (VAPP) was evaluated in Hodgkin's disease. Subjects were either far advanced cases or relapsing after MOPP and/or radiation therapy. 50 cases were evaluable. After 6 months of treatment 80% of the cases achieved a complete remission. After 30 months 87% of the patients still survive and 60% were still in complete remission. The good tolerance of this chemotherapeutic combination and the results described above, suggest that VAPP may be useful in all cases when MOPP is not well tolerated or is not active.
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002648:Child; D004317:Doxorubicin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D012075:Remission, Spontaneous; D014750:Vincristine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D011344:Procarbazine; D014750:Vincristine; D004317:Doxorubicin; D011241:Prednisone
Valutazione a distanze dell'attività sul morbo di hodgkin evoluto di un protocollo chemioterapico utilizzante vincristina, adriamicina, procarbazina, prednisone (VAPP).